tiprankstipranks
Perspective Therapeutics Reports Q1 2025 Results and Updates
PremiumCompany AnnouncementsPerspective Therapeutics Reports Q1 2025 Results and Updates
16d ago
Buy Rating for Perspective Therapeutics: Promising Advancements in Targeted Radioligand Therapy
Premium
Ratings
Buy Rating for Perspective Therapeutics: Promising Advancements in Targeted Radioligand Therapy
28d ago
Perspective Therapeutics announces first patient dosed with PSV359
Premium
The Fly
Perspective Therapeutics announces first patient dosed with PSV359
30d ago
Perspective Therapeutics price target lowered to $10 from $21 at Truist
PremiumThe FlyPerspective Therapeutics price target lowered to $10 from $21 at Truist
2M ago
Positive Outlook for Perspective Therapeutics Despite Wider Net Loss, Supported by Strong Cash Position and Upcoming Catalysts
Premium
Ratings
Positive Outlook for Perspective Therapeutics Despite Wider Net Loss, Supported by Strong Cash Position and Upcoming Catalysts
2M ago
Perspective Therapeutics management to meet with Oppenheimer
Premium
The Fly
Perspective Therapeutics management to meet with Oppenheimer
2M ago
Promising Clinical Developments and Unique Mechanism Drive Buy Rating for Perspective Therapeutics
PremiumRatingsPromising Clinical Developments and Unique Mechanism Drive Buy Rating for Perspective Therapeutics
2M ago
Promising Developments and Strategic Trial Design Justify Buy Rating for Perspective Therapeutics
Premium
Ratings
Promising Developments and Strategic Trial Design Justify Buy Rating for Perspective Therapeutics
2M ago
Perspective Therapeutics says first patient dosed in Phase 1/2a trial of VMT01
Premium
The Fly
Perspective Therapeutics says first patient dosed in Phase 1/2a trial of VMT01
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100